[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![AlertsAndNews Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::818548189724807168.png) AlertsAndNews [@AlertsAndNews](/creator/twitter/AlertsAndNews) on x 5338 followers
Created: 2025-06-02 02:31:27 UTC

$ARVN Arvinas & Pfizer’s Vepdegestrant Shows Strong PFS Benefit in ESR1-Mutant Breast Cancer

Phase X VERITAC-2 trial results presented at ASCO show vepdegestrant significantly improved progression-free survival (PFS) in patients with ESR1-mutant, ER+/HER2- advanced breast cancer. Median PFS was XXX months vs. XXX months for fulvestrant, cutting risk of progression or death by XX% (HR=0.57). While the ITT population did not meet statistical significance (HR=0.83, p=0.07), vepdegestrant was well tolerated with low discontinuation and GI event rates. It's the first PROTAC to demonstrate benefit in a Phase X breast cancer trial.


XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1929365213964284116/c:line.svg)

**Related Topics**
[$arvn](/topic/$arvn)

[Post Link](https://x.com/AlertsAndNews/status/1929365213964284116)